Elastase-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Neutrophil Elastase (ELANE; UniProt P08246), HEK293-expressed. Serine protease used for substrate cleavage assays, inhibitor IC50 profiling, and antibody validation in neutrophil biology research.
Expression system
HEK293
Cat. #
REC-Elastase2

In stock

SKU
REC-Elastase2
$498.00

Target Overview

Elastase-2 (ELANE; UniProt P08246) is a chymotrypsin-family serine protease (EC 3.4.21.37) stored in azurophil granules and released by activated neutrophils. The mature human protein spans a 267-amino-acid sequence and carries the canonical Ser-His-Asp catalytic triad characteristic of neutrophil serine proteases. This recombinant form is produced in HEK293 mammalian cells, a system that supports native-like disulfide bonding and glycosylation patterns relevant to the physiological enzyme. HEK293 expression is preferred over prokaryotic systems for serine proteases of this family because it reduces the risk of misfolded, inactive material and avoids refolding artefacts that can confound kinetic measurements. In the laboratory, this recombinant is used primarily in three contexts. First, substrate cleavage assays: Elastase-2 efficiently hydrolyses small fluorogenic peptides (e.g., MeOSuc-AAPV-AMC) and macromolecular substrates including elastin, fibronectin, and outer membrane proteins, making it suitable for continuous fluorescence-based activity measurements and end-point gel assays. Second, inhibitor profiling: the enzyme is widely used to determine IC50 values for synthetic and natural-product inhibitors in competitive and tight-binding inhibitor formats. Third, antibody validation: researchers running Western blot or IHC experiments can use this recombinant as a positive-control antigen to confirm antibody specificity — it is cross-referenced with the matched Triple Point Biologics anti-Elastase-2 antibody (SKU: RP-Elastase2), produced and validated in-house since 1994. The protein is suitable for kinetic characterisation, active-site titration, substrate identification by mass spectrometry, and neutrophil extracellular trap (NET) biology assays involving histone H4 cleavage.

Background

Neutrophil elastase (ELANE; also known as Human Leukocyte Elastase, HLE, PMN elastase, and Medullasin) is one of the principal effector proteases of the innate immune system. Constitutively expressed in myeloid precursors and packaged into azurophil granules during granulopoiesis, it is released into the phagolysosomal lumen and extracellular space upon neutrophil activation. Its broad substrate range — elastin, collagen IV, fibronectin, laminin, complement components, and bacterial outer membrane proteins — positions it at the intersection of antimicrobial defence, coagulation regulation, and inflammatory signalling. In microbicidal contexts, published studies have shown ELANE degrades outer membrane protein A (OmpA) in E. coli and K. pneumoniae, contributing to gram-negative bacterial killing. The enzyme also participates in NET (neutrophil extracellular trap) formation: following MPO-directed nuclear translocation, ELANE cleaves histone H4, facilitating chromatin decondensation and DNA extrusion. This pathway has been characterised in detail and is an active area of in-vitro reconstitution research using recombinant ELANE. Zhang et al. (2026, Cell Commun Signal) provide a comprehensive review of ELANE signalling across congenital haematopoietic failure, immune microenvironment crosstalk, and targeted intervention strategies, underscoring the enzyme's breadth as a research target. ELANE mutations are investigated as drivers of cyclic and severe congenital neutropenia (SCN), conditions in which aberrant ELANE activity or misfolding is hypothesised to trigger unfolded protein response pathways in granulocyte precursors. Rutkowska-Zapała et al. (2026, Genes Immun) characterised novel ELANE mutations and their effects on NET formation in cyclic neutropenia patients, illustrating how recombinant wild-type enzyme serves as the reference benchmark in such functional comparisons. In the context of chronic obstructive pulmonary disease (COPD) and related inflammatory lung conditions, ELANE-mediated degradation of extracellular matrix components in airway epithelium is studied as a mechanism of tissue remodelling. Several recent computational and biochemical studies (Zaman SR et al., 2026, Immunobiology; Abdul Rahman I et al., 2026, J Comput Aided Mol Des) have employed recombinant human neutrophil elastase to validate in-silico-selected natural-product inhibitors through enzymatic IC50 assays, demonstrating the protein's routine utility in inhibitor triage pipelines. Researchers investigating coagulation will find ELANE relevant to its documented cleavage of tissue factor pathway inhibitor (TFPI) and its role in potentiating platelet aggregation via integrin αIIb/β3. Recombinant ELANE is the standard reagent for reconstituting these cleavage events in cell-free systems. Validated human species reactivity; cross-species reactivity has not been confirmed for this recombinant.

Applications

  • Fluorogenic peptide substrate cleavage assay (e.g., MeOSuc-AAPV-AMC) with continuous fluorescence readout
  • Inhibitor IC50 determination for synthetic and natural-product HNE inhibitor candidates
  • Antibody validation positive-control antigen for Western blot and IHC (pair with Triple Point anti-Elastase-2, SKU: RP-Elastase2)
  • In vitro NET formation reconstitution: histone H4 cleavage and chromatin decondensation assay
  • TFPI and coagulation-factor cleavage assay in cell-free plasma or defined-component systems
  • Bacterial outer membrane protein (OmpA) degradation assay for microbicidal activity characterisation
  • Active-site titration using mechanism-based inhibitors (e.g., α1-antitrypsin or sivelestat) to determine functional enzyme concentration

References

  1. Rutkowska-Zapała M et al. Neutrophil extracellular traps formation driven by novel ELANE mutations in cyclic neutropenia patients. Genes Immun. 2026. doi:10.1038/s41435-026-00403-4 PMID: 42337056
  2. Abdul Rahman I et al. Exploring the HNE-inhibitory potential of in silico selected Moringa oleifera defense proteins. J Comput Aided Mol Des. 2026. doi:10.1007/s10822-026-00864-9 PMID: 42334676
  3. Zaman SR et al. Computational identification of natural inhibitors of human neutrophil elastase as potential therapeutics for chronic obstructive pulmonary disease. Immunobiology. 2026. doi:10.1016/j.imbio.2026.153209 PMID: 42322881
  4. Zhang F. The multidimensional signaling of ELANE: from congenital hematopoietic failure to immune microenvironment crosstalk and targeted interventions. Cell Commun Signal. 2026. doi:10.1186/s12964-026-03009-5 PMID: 42310651
  5. Jones AW et al. Effects of acute bovine colostrum supplementation on immune responses to prolonged cycling: a randomised crossover trial. Eur J Nutr. 2026. doi:10.1007/s00394-026-04016-5 PMID: 42249952

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Azurophilic granules; neutrophils; secreted on activation

Frequently Asked Questions

What molecular weight should I expect for recombinant Elastase-2 on SDS-PAGE or Western blot?

The mature human Elastase-2 (ELANE, UniProt P08246) has a predicted molecular weight of ~29 kDa based on its 267-amino-acid sequence. However, because this recombinant is expressed in HEK293 mammalian cells and carries native-like N-linked glycosylation, the observed band on SDS-PAGE typically migrates at approximately 33–36 kDa under reducing conditions. Under non-reducing conditions, disulfide-dependent compaction can shift apparent migration slightly. Always run a prestained marker in the 25–50 kDa range when confirming identity.

Is this recombinant Elastase-2 the mature processed form or does it include the propeptide?

This recombinant corresponds to the mature, active form of human Elastase-2 — the propeptide has been removed during processing, consistent with the physiologically relevant enzyme stored in neutrophil azurophil granules. It retains the canonical Ser-His-Asp catalytic triad (EC 3.4.21.37). Because propeptide-free material can autoactivate at neutral pH, we recommend keeping the enzyme on ice during setup and adding substrate immediately after dilution into assay buffer to avoid activity loss from autoproteolysis.

What substrates does recombinant Elastase-2 cleave, and which fluorogenic peptide is best for activity assays?

Elastase-2 efficiently hydrolyses the fluorogenic peptide MeOSuc-AAPV-AMC (ex/em ~360/460 nm), which is the most widely cited small-molecule substrate for kinetic characterization and inhibitor screening. Macromolecular substrates include elastin, fibronectin, and outer membrane protein A (OmpA). For routine activity confirmation or IC50 measurements, MeOSuc-AAPV-AMC at 100–200 µM in 50 mM Tris-HCl pH 7.5, 150 mM NaCl is a practical starting point. Substrate concentration should bracket the reported Km (~150 µM) to allow reliable Michaelis–Menten fitting.

What buffer conditions work best for Elastase-2 (Recombinant) activity assays, and can I use PBS?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is also a suitable assay buffer backbone. For activity assays, omit glycerol or dilute it to ≤1% to avoid viscosity effects on fluorescence readings. PBS (pH 7.4) is compatible but slightly suboptimal; Elastase-2 activity is pH-sensitive, and peak activity is typically reported between pH 7.4–8.0. Avoid buffers containing primary amines (e.g., Tris above 100 mM at low enzyme concentrations) or reducing agents such as DTT or TCEP, which can disrupt disulfide bonds critical for catalytic geometry.

What starting enzyme concentration should I use for a recombinant Elastase-2 activity or inhibition assay?

A starting concentration of 1–10 nM recombinant Elastase-2 in assay buffer is appropriate for fluorogenic peptide cleavage assays using MeOSuc-AAPV-AMC at 100–200 µM. For macromolecular substrate assays (elastin, fibronectin), 50–200 nM is more typical to observe meaningful turnover within a 30–60 min window. For IC50 determinations, keep enzyme concentration at or below the Ki of your inhibitor to avoid tight-binding artifacts — generally 2–5 nM works well for known neutrophil elastase inhibitors. Titrate in pilot experiments before committing to a full inhibitor panel.

Can I use recombinant Elastase-2 as a Western blot positive control with the matched anti-Elastase-2 antibody?

Yes — this is one of the primary intended uses of REC-Elastase2 alongside the matched rabbit polyclonal antibody (SKU: RP-Elastase2, available at /anti-elastase-2-rabbit-polyclonal-antibody). Because both are produced and validated in the same laboratory, epitope compatibility is confirmed rather than assumed. Load 20–50 ng of recombinant protein per lane under reducing conditions; you should detect a clear band at ~33–36 kDa with RP-Elastase2. This pairing is especially useful when setting up detection in new cell or tissue lysates where endogenous expression levels are uncertain.

How much recombinant Elastase-2 should I load for a Western blot positive control, and what dilution of RP-Elastase2 antibody should I use?

Load 20–50 ng of REC-Elastase2 per lane for a reliable positive control band at ~33–36 kDa. For the matched rabbit polyclonal RP-Elastase2, a primary antibody dilution of 1:1,000–1:2,000 in 5% non-fat dry milk or BSA/TBST typically yields a clean signal with minimal background in our hands. Exposure times will vary by detection system, but with HRP-conjugated secondary antibodies and chemiluminescent substrate, a 30–60 second exposure is usually sufficient at the 20–50 ng loading range. Reduce loading to 5–10 ng if signal is saturating.

How should I store and handle recombinant Elastase-2 to maintain activity, and what is the shelf life?

REC-Elastase2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and should be stored at -20°C in single-use aliquots. Avoid repeated freeze-thaw cycles — each cycle can cause measurable loss of serine protease activity due to partial unfolding at the active site. Once thawed, keep on ice and use within 4–8 hours. When stored correctly, activity is stable for at least 12 months from the date of receipt. For dilute working stocks (<10 nM), add carrier protein (0.1% BSA) to the dilution buffer to prevent adsorptive losses to tube walls.

Validation imagery coming soon

Western blot validation figures for REC-Elastase2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →